Tarsus Pharmaceuticals, Inc. TARS Operating lease modification
Operating lease modification at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept tars:LeaseModificationExpenseNonCash.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating lease modification.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s operating lease modification?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating lease modification of $0 in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s operating lease modification changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s operating lease modification decreased by 100.0% year-over-year, from $269.5K to $0.
- What does operating lease modification mean?
- This captures the non-cash accounting adjustments resulting from changes to the terms of existing lease agreements, such as extensions or modifications to leased space. It reflects the impact of operational changes on the company's lease portfolio valuation. This metric helps analysts isolate accounting volatility from core operational cash performance.